Category: Latest News
-
Novo Nordisk Climbs Following FDA Approval of Wegovy for Liver Disease
Shares of Novo Nordisk (NYSE:NVO) rose 2.4% in pre-market trading Monday in New York after the FDA approved Wegovy for treating metabolic dysfunction-associated steatohepatitis (MASH). Previously recognized for its weight-loss benefits, Wegovy now expands its use to address liver disease. The FDA granted accelerated approval, marking Wegovy as the first GLP-1-based therapy indicated for adults…
-
Investors Move to Take Soho House Private in $2.7 Billion Deal
A consortium of investors led by MCR Hotels and CEO Tyler Morse has agreed to take Soho House & Co. (NYSE:SHCO) private. MCR owns notable New York properties, including the High Line, Gramercy Park, and other landmark hotels. The deal values the members’ club and hotel operator at around $2.7 billion, including debt. Shareholders are…
-
Pentair to Acquire Hydra-Stop in $290 Million Cash Deal
Pentair plc (NYSE:PNR) has signed a definitive agreement to purchase Hydra-Stop LLC, a specialist in valve solutions, from Madison Industries. The deal is valued at roughly $290 million in cash, subject to standard closing adjustments, and could finalize by the end of 2025 pending regulatory approval. After factoring in estimated tax benefits of around $50…
-
Goldman Sachs Strengthens India Footprint with New Mumbai Office
Goldman Sachs (NYSE:GS) has bolstered its operations in India, the world’s fourth-largest economy, by launching a new office in Worli, Mumbai’s premier financial hub. The new facility spans over 6,500 square meters, a 50% increase compared with the bank’s previous Mumbai location. It features modern meeting rooms equipped with Zoom technology, flexible workstations, collaborative spaces,…
-
Thoma Bravo Eyes Dayforce Acquisition, Driving Shares Up
Shares of Dayforce Inc. (NYSE:DAY) jumped more than 27% in premarket trading Monday, reaching $67.41, after reports surfaced that private equity firm Thoma Bravo (NYSE:TBA) is exploring a potential purchase of the human resources software company. The stock had closed at $52.88 previously. Sources indicate that talks are at an advanced stage, with a possible…
-
Oil Prices Creep Up Ahead of Trump-Zelensky Talks
Oil prices inched higher on Monday as markets awaited a high-stakes meeting in Washington between U.S. President Donald Trump and Ukrainian President Volodymyr Zelensky, with traders weighing the potential impact on global supply. By 07:45 ET (11:45 GMT), October Brent crude futures rose 0.5% to $66.18 per barrel, while West Texas Intermediate (WTI) futures gained…
-
Nvidia Poised for Another Strong Quarter, Long-Term Outlook Remains Bright: Morgan Stanley
Morgan Stanley expects Nvidia (NASDAQ:NVDA) to deliver another set of robust results next week, even as expectations remain elevated. The firm lifted its price target to $206 from $200 and kept its Overweight rating in place, emphasizing confidence in the chipmaker’s growth trajectory through 2026. “We expect a strong quarter and outlook, but we’re a…
-
UnitedHealth Stock Extends Rally as Buffett’s Berkshire Buys Big Stake
UnitedHealth Group Inc. (NYSE:UNH) extended its rebound Monday, climbing another 3% in premarket trading after soaring 12% on Friday. The surge followed revelations that Warren Buffett’s Berkshire Hathaway Inc. (NYSE:BRK.B) has taken a sizable stake in the health insurer. Regulatory filings show Berkshire acquired 5 million shares of UnitedHealth during the second quarter, a move…
-
Enlivex Stocks Rises On Encouraging Phase IIa Data for Allocetra in Knee Osteoarthritis
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) announced promising three-month outcomes from its Phase IIa study evaluating Allocetra in patients with moderate-to-severe knee osteoarthritis. The company’s stock surged 18% following the announcement. The randomized, double-blind, placebo-controlled, multi-center trial demonstrated a 24% reduction in knee pain and a 26% improvement in function across the modified intention-to-treat population treated with…
-
Madrigal Shares Slip After FDA Clears Novo Nordisk’s Wegovy for MASH
Madrigal Pharmaceuticals (NASDAQ:MDGL) fell 4% in pre-market trading Monday after the U.S. Food and Drug Administration granted approval to Novo Nordisk’s (NYSE:NVO) Wegovy for treating adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis. The green light from regulators adds new competitive pressure for Madrigal, whose lead therapy Rezdiffra is also…